system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Animals, Antigens, Differentiation, B-Lymphocyte, CD4-Positive T-Lymphocytes, COS Cells, Cancer Vaccines, Cell Line, Tumor, Cell Proliferation, Cercopithecus aethiops, Dendritic Cells, HLA-DR Antigens, Histocompatibility Antigens Class II, Humans, Male, Mice, Mice, Inbred C57BL, N-Acetylglucosaminyltransferases, Pancreatic Neoplasms, Recombinant Fusion Proteins, Time Factors, Transfection.
user
Does pancreas carcinoma antigen fused to invariant chain elicit T-cell response and tumor growth inhibition? Context: The major histocompatibility complex class II chaperone invariant chain (Ii) is widely used as a carrier for inserted antigenic sequences and their introduction into the class II processing pathway. The tumor-associated antigen core 2beta 1,6 N-acetylglucosaminyltransferase (C2GnT), a glycosyltransferase present in human pancreatic tumor cells, is not expressed by normal pancreatic tissues. A set of expression vectors was engineered where the class II binding region of Ii was replaced by C2GnT-derived sequences. We investigated in vitro whether dendritic cells transfected with Ii-C2GnT constructs were capable to stimulate proliferation of CD4 T cells. We also tested whether vaccination with Ii-C2GnT would protect mice from tumor development. Invariant chain-C2GnT fusion proteins bind to human DR1, DR3, DR4 and to mouse I-A molecules. Our results demonstrate that the plasmid DNA encoding the C2GnT epitope embedded in Ii induces tumor-specific T-cell responses. Mice immunized with the Ii constructs showed reduced growth of Panc02 pancreatic tumor cells.
assistant
Therefore, Ii clipped with the tumor-associated antigen C2GnT shows promise for the treatment of pancreatic cancer. Final Decision: yes